Using rTMS to treat negative symptoms of schizophrenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of repetitive Transcranial Magnetic Stimulation (rTMS) in alleviating negative symptoms associated with schizophrenia in real-world settings. It proposes four different rTMS protocols tailored to individual patient tolerances, with treatment durations ranging from 2 to 4 weeks. Following the treatment, participants will be monitored for a period of 3 months to assess any relapses in symptoms, using the Scale for the Assessment of Negative Symptoms (SANS) for evaluation. The study aims to establish a regulatory framework for rTMS treatments under these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient over 18 years of age
* Patient diagnosed with schizophrenia according to the DSM-V criteria (Diagnostic and Statistical Manual of Mental Disorder V5, 2013)
* Stable drug treatment for at least 4 weeks
* Presence or persistence of negative symptoms in the foreground:

Negative PANSS score ⩾21, positive PANSS score ⩽24

* Patient (or legal representative) willing to participate in the study and having signed an informed consent
* Patient fluent in the French language
* Affiliation to a social security scheme

Exclusion Criteria:

* Present a contraindication to TMS: intracranial foreign body, unstabilized epilepsy, cochlear implant, pace-maker
* Presence of an unstabilized medical condition
* Pregnant woman
* Woman of childbearing potential and without effective contraception
* Breastfeeding woman

Where it's running

• Etablissement Public de Santé de Ville-Evrard
  Neuilly-sur-Marne, France Recruiting

Study contacts

• Principal investigator: Dominique Januel — Clinical research unit, EPS Ville Evrard
• Study coordinator: Youcef Bencherif
• Email: urc@epsve.fr
• Phone: +33 1 43 09 32 32

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• Validation of Lithuanian mental health assessment scales

  This study is testing new Lithuanian mental health scales to see if they accurately measure symptoms of schizophrenia in adults aged 18 to 65.

  Recruiting at 2 sites Lithuanian University of Health Sciences · Kaunas and 1 other locations · NCT06278532

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• XEP527 in stable schizophrenia: safety and how it behaves in the body

  This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.

  Recruiting Phase 1 Novartis · Bentonville, Arkansas · NCT07908680

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

• Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder

  This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.

  Recruiting Bosnalijek D.D · Sarajevo · NCT07858565

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.